Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Senior Officer Adrian J. Haigh sold 22,223 shares of the company's stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of C$9.32, for a total transaction of C$207,029.47.
Adrian J. Haigh also recently made the following trade(s):
- On Monday, April 15th, Adrian J. Haigh purchased 22,222 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average price of C$2.31 per share, for a total transaction of C$51,332.82.
Fennec Pharmaceuticals Stock Performance
Shares of Fennec Pharmaceuticals stock opened at C$12.80 on Wednesday. The stock has a market cap of C$346.11 million, a price-to-earnings ratio of -12.55 and a beta of 0.35. The firm's 50-day moving average is C$13.50 and its 200 day moving average is C$12.74. Fennec Pharmaceuticals Inc. has a 1 year low of C$9.27 and a 1 year high of C$15.43. The company has a debt-to-equity ratio of 881.09, a current ratio of 3.29 and a quick ratio of 10.17.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.16). The company had revenue of C$13.25 million for the quarter, compared to the consensus estimate of C$12.88 million. Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%. Sell-side analysts anticipate that Fennec Pharmaceuticals Inc. will post 0.4202312 EPS for the current fiscal year.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
